bevacizumab,panitumumab,cisplatin
takeda,amgen,roche
[]
paradigm exploratory analysis examining patients by ctdna markers can predict benefit to anti-egfr therapy. exciting to see this technology come to bedside to guide therapy in real time for our crc patients. #gi23 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.